2-甲基-4-氨基-5-氟吡啶 | 1211590-22-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-甲基-4-氨基-5-氟吡啶
• 英文名称: 5-fluoro-2-methylpyridin-4-amine
• 英文别名: 4-Amino-5-fluoro-2-methylpyridine
• CAS: 1211590-22-5
• 化学式: C₆H₇FN₂
• 分子量: 126.133
• InChiKey: UQCCFTSJZJJSJI-UHFFFAOYSA-N

物化性质

• 沸点：
  216.9±35.0 °C(Predicted)
• 密度：
  1.196±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H320,H335

反应信息

• 作为产物：
  描述：

  tert-butyl (5-fluoro-2-methylpyridin-4-yl)carbamate 在 三氟乙酸 作用下， 反应 1.0h， 以32 mg的产率得到2-甲基-4-氨基-5-氟吡啶
  参考文献：
  名称：

  NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

  摘要：

  公开号：

  EP2589592B1

文献信息

• [EN] PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF<br/>[FR] DÉRIVÉS DE PYRIMIDINE ET DE PYRIDINE ET LEUR UTILISATION POUR TRAITER OU PRÉVENIR LA GRIPPE, OU POUR ATTÉNUER SES SYMPTÔMES
  申请人：SAVIRA PHARMACEUTICALS GMBH

  公开号：WO2017133667A1

  公开（公告）日：2017-08-10

  Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza.

  本文提供的是一种化合物，其化学式为（I），可以是药用盐、溶剂合物、多型体、前药、共药、共晶、互变异构体、消旋体、对映体或二对映体，或它们的混合物形式，该化合物在治疗、改善或预防流感方面具有用处。
• [EN] DIHYDROOROTATE DEHYDROGENASE INHIBITORS<br/>[FR] INHIBITEURS DE DIHYDROOROTATE DÉSHYDROGÉNASE
  申请人：JANSSEN BIOTECH INC

  公开号：WO2020144638A1

  公开（公告）日：2020-07-16

  Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows: wherein R1a, R1b, R2, and R3, are defined herein.

  揭示了一种通过调节DHODH来治疗受影响的疾病、疾病或医疗状况的化合物、组合物和方法。这些化合物由以下式（I）表示：其中R1a、R1b、R2和R3在此处定义。
• NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF
  申请人：FUJIWARA Hideyasu

  公开号：US20130116430A1

  公开（公告）日：2013-05-09

  An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl group, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R 3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R 4 and R 5 each independently represent a hydrogen atom; and R 2 and R 4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

  本发明的目的是提供一种具有优异的Syk抑制活性的化合物和制药组合物。本发明提供了一种由以下式(I)表示的烟酰胺衍生物（其中R1表示卤素原子；R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基，每种均可选地具有至少一个取代基；R3表示芳基或杂环基，每种均可选地具有至少一个取代基；R4和R5各自独立地表示氢原子；且R2和R4可以与它们结合的氮原子一起形成具有至少一个取代基的环状氨基团）或其盐，并且用于治疗Syk相关疾病的制药组合物包括该烟酰胺衍生物或其盐。
• NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20160237090A1

  公开（公告）日：2016-08-18

  The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R 1 to R 4 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.

  本发明涉及化合物(I)的公式，或其药学上可接受的盐、对映体或二面体异构体，其中R1到R4如上所述。这些化合物可能对治疗或预防乙型肝炎病毒感染有用。
• Substituted 6-azabenzimidazole compounds
  申请人：Gilead Sciences, Inc.

  公开号：US11071730B2

  公开（公告）日：2021-07-27

  The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

  本公开一般涉及某些 6-氮杂苯并咪唑化合物、包含所述化合物的药物组合物以及制造和使用所述化合物和药物组合物的方法。本文公开的化合物和组合物可用于治疗或预防可被造血祖细胞激酶 1（HPK1）抑制剂改变的疾病、失调或感染，如 HBV、HIV、癌症和/或过度增殖性疾病。